A new orphan drug player - Amryt Pharma Plc- is coming to the London stock market heralding a promising pipeline and experienced leadership, arriving via a reverse takeover with Alternative Investment Market (AIM)-listed investment firm Fastnet Equity PLC.
A new orphan drug player - Amryt Pharma Plc- is coming to the London stock market heralding a promising pipeline and experienced leadership, arriving via a reverse takeover with Alternative Investment Market (AIM)-listed investment firm Fastnet Equity PLC.
The result will be a drug company with big plans and a product that is already on the market. That...
Create an account to read this article
Already a subscriber?
The Phase IIb study failed its primary and a key secondary endpoint, but showed activity on another key secondary and an exploratory endpoint.
The Danish medical dermatology specialist boosts its sales force ahead of the launch of Anzupgo.
Sun’s Leqselvi goes up against Lilly's Olumiant and Pfizer's Litfulo, which currently has the broadest label, in the US alopecia market. Can it shake things up early, amid growing activity in the space with several new mechanisms of action being investigated?
Paying €90m upfront for rights to generalized pustular psoriasis drug.
The BRUIN CLL-314 trial was designed to show noninferiority, but the p-value indicated a favorable result for Jaypirca in both the pre-treated and intent-to-treat populations.
Its multibillion dollar investment demonstrates the importance of the US to AstraZeneca, with half of its targeted $80bn revenues by 2030 set to come from the country, Pascal Soriot said as it presented strong second-quarter results.
The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.
